You just read:

OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

News provided by

OncoSec Medical Incorporated

Dec 14, 2017, 07:00 EST